Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) recorded a decline in its consolidated attributable profit to 12.5 billion Indian rupees in the fiscal second quarter ended Sept. 30 against 14.8 billion rupees a year ago.
Earnings per share contracted to 15.05 rupees compared with a year-ago figure of 17.76 rupees, according to a filing to the stock exchanges on Tuesday by the pharmaceutical company.
Revenue from operations in fiscal Q2 increased to 80.2 billion rupees from 68.8 billion rupees a year earlier.
Shares of the company were up over 1% in recent trade.
Price (INR): ₹1318.10, Change: ₹+15, Percent Change: +1.16%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.